Ocugen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
47.9%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| OCU400 Phase 3 liMeliGhT Topline Data | 31 Mar 2027 |
| OCU410ST Phase 2/3 GARDian3 Topline Data | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
OCU400 Phase 3 liMeliGhT Trial Enrollment Quarterly140.0Target: 140 (Enrollment Completed)
OCU410ST GARDian3 Phase 2/3 Trial Enrollment Quarterly63.0Target: 63 (Enrollment Completed)
Cash and Cash Equivalents (including restricted cash) Quarterly32.2MTarget: 112100000 (Post-Convertible Note Offering & Debt Payoff)
Watch Items
- OCU400 Rolling BLA SubmissionTrigger: Initiation of rolling submissionAction: Monitor regulatory filings and FDA feedback starting Q3 2026
- OCU410ST Interim Outcome AnalysisTrigger: 24 subjects completing 8-month assessmentsAction: Review masked interim efficacy and safety data in Q3 2026
- OCU410 Phase 3 Registrational Trial InitiationTrigger: Regulatory alignment with FDA and EMAAction: Track trial initiation and first patient dosing planned for Q3 2026
Research as of 19 Jun 2026